Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR-SEQUENCE: Panitumumab vs Bevacizumab Sequencing in mCRC
NCT03635021Phase 3Active, not recruiting
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Oct 2018
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of panitumumab in colorectal cancer (CRC) (2 arms), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Progression-Free Survival Rate at 35 months. Started Oct 2018; status: active, not recruiting.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03635021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635021.